|1.||Remington, Gary: 3 articles (09/2015 - 07/2013)|
|2.||Sabbagh, Marwan: 2 articles (01/2015 - 06/2014)|
|3.||Symmans, W Fraser: 2 articles (05/2014 - 07/2012)|
|4.||Pusztai, Lajos: 2 articles (05/2014 - 07/2012)|
|5.||Rao, Naren P: 2 articles (02/2014 - 07/2013)|
|6.||Menter, Alan: 2 articles (04/2012 - 08/2011)|
|7.||Löscher, Wolfgang: 2 articles (01/2012 - 05/2009)|
|8.||Walker, Karen: 2 articles (11/2010 - 11/2010)|
|9.||Mozley, P David: 2 articles (01/2010 - 03/2003)|
|10.||Agulnik, Mark: 2 articles (06/2008 - 02/2008)|
12/01/2015 - "Segmental endotoxin challenge with lipopolysaccharide (LPS) can be used as a pharmacodynamic model to safely induce a transient airway inflammation in the peripheral lung of healthy subjects and to test the anti-inflammatory efficacy of investigational new drugs. "
12/01/2007 - "A new, easy-to-use and robust activity index predicting mucosal inflammation is highly needed to assess the response to investigational drugs in trials and the effect of therapeutical interventions in clinical practice."
01/01/2012 - "The cardiovascular profile of other biologic therapies for the treatment of RA has not been adequately studied, including of investigational drugs that improve systemic inflammation but alter traditional cardiovascular risk factors. "
12/01/2006 - "Ongoing studies with these investigational drugs should provide new insights into optimal strategies to disrupt Bcl-2 survival functions to selectively kill cancer cells."
11/01/2002 - "The success of these studies confirms the importance of the continued search for new investigational drugs in all solid tumors."
05/15/1993 - "The success of these studies confirms the importance of the continued search for new investigational drugs in all solid tumors."
10/01/2014 - "Although many investigational drugs, approved first for other cancers, have been subsequently evaluated for the management of GIST, few have greatly affected the overall survival of patients with advanced disease. "
11/01/2010 - "Many investigational drugs from these classes are currently being evaluated to assess their role in tumor therapy. "
|4.||Breast Neoplasms (Breast Cancer)
05/01/2014 - "The aim of this study was to assess the frequency of potentially actionable genomic alterations in breast cancer that could be targeted with approved agents or investigational drugs in clinical trials using a next-generation sequencing-based genomic profiling assay performed in a Clinical Laboratory Improvement Amendments-certified and College of American Pathologists-accredited commercial laboratory. "
07/01/2012 - "The purpose of this study was to identify mutations in genes that may be targeted with currently available investigational drugs in the three major breast cancer subtypes (ER+/HER2-, HER2+, and Triple Negative). "
08/01/1994 - "For more than 10 years, the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Breast Cancer Site Group has focused primarily on trials of adjuvant therapy and of investigational new drugs (IND). "
01/01/2013 - "High failure rates of new investigational drugs have impaired the development of breast cancer therapies. "
02/01/2012 - "Targeting the subtypes of breast cancer: rethinking investigational drugs."
|5.||Alzheimer Disease (Alzheimer's Disease)
09/01/2010 - "Results of clinical trials with many of these investigational drugs have been disappointing, perhaps because of their use with patients in advanced stages of Alzheimer disease. "
07/01/2010 - "The launch of a new initiative to share data from failed clinical trials of investigational drugs for Alzheimer's disease provides both a promising opportunity to improve drug development in this field, as well as a novel mechanism to learn more from negative trials in general."
12/01/2015 - "Investigational drugs targeting 5-HT6 receptors for the treatment of Alzheimer's disease."
06/01/2014 - "Investigational drugs in Alzheimer's disease: current progress."
12/01/2015 - "The article is based on a search for investigational drugs using the key words '5-HT6', 'cognition', 'dementia', 'Alzheimer's disease', 'Phase II' and 'Phase III' in various databases and from conference abstracts. "
|1.||Dopamine Receptors (Dopamine Receptor)
|2.||Biological Markers (Surrogate Marker)
|4.||Protein Kinases (Protein Kinase)
|7.||Trimethoprim-Sulfamethoxazole Combination (Co-Trimoxazole)
|1.||Drug Therapy (Chemotherapy)
|2.||Molecular Targeted Therapy
|3.||Investigational Therapies (Experimental Therapy)
|4.||Angioplasty (Angioplasty, Transluminal)